半乳糖凝集素3通过Dectin-1激活增强血小板聚集和血栓形成
在冠心病患者中,血浆Galectin-3浓度与血小板聚集及全血血栓形成呈强正相关。机制研究显示Galectin-3结合并激活血小板Dectin-1受体,促进血小板高反应性;TD139抑制Galectin-3可抑制血栓形成且不增加出血。
要点
- 冠心病患者血浆Galectin-3与血小板聚集及血栓形成正相关
- Galectin-3通过Dectin-1-Syk信号通路增强血小板活化
- TD139抑制Galectin-3介导的血栓形成且不加重出血
核心结论
- Galectin-3是冠心病中血小板高反应性和血栓形成的新型正向调节因子。
- Galectin-3抑制剂TD139具有强效抗血栓作用且不增加出血风险,可能成为高血浆Galectin-3患者的潜在抗血小板药物。
研究设计与样本
- 转化研究:在冠心病患者中观察血浆Galectin-3与血小板聚集及全血血栓形成的相关性。
- 机制研究使用Dectin-1抑制剂laminarin和Dectin-1-/-小鼠。
- TD139在ApoE-/-小鼠中评估抗血栓效果及出血风险。
主要发现
- 冠心病患者血浆Galectin-3浓度与血小板聚集或全血血栓形成呈强正相关。
- Galectin-3直接增强血小板活化和体内血栓形成。
- Galectin-3结合并激活血小板Dectin-1,磷酸化Syk,增加Ca2+内流、PKC活化和ROS产生。
- TD139浓度依赖性抑制Galectin-3增强的血小板活化,抑制闭塞性血栓且不加重出血。
- TD139抑制微血管血栓,保护ApoE-/-小鼠心脏免受心肌缺血再灌注损伤。
关键数值与推荐
- 血浆Galectin-3获II类推荐用于心力衰竭管理。
- TD139为处于II期临床试验的Galectin-3抑制剂。
临床怎么用
- 高血浆Galectin-3水平的冠心病患者可能从Galectin-3抑制剂抗血小板治疗中获益。
- TD139在不增加出血风险的前提下具有抗血栓潜力。
局限性
- 研究为临床前及转化研究,尚需临床试验验证Galectin-3抑制剂在患者中的疗效和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Galectin-3, a β-galactoside-binding lectin, is abnormally increased in cardiovascular disease. Plasma Galectin-3 receives a Class II recommendation for heart failure management and has been extensively studied for multiple cellular functions. The direct effects of Galectin-3 on platelet activation remain unclear. This study explores the direct effects of Galectin-3 on platelet activation and thrombosis. METHODS AND RESULTS: A strong positive correlation between plasma Galectin-3 concentration and platelet aggregation or whole blood thrombus formation was observed in patients with coronary artery disease (CAD). Multiple platelet function studies demonstrated that Galectin-3 directly potentiated platelet activation and in vivo thrombosis. Mechanistic studies using the Dectin-1 inhibitor, laminarin, and Dectin-1-/- mice revealed that Galectin-3 bound to and activated Dectin-1, a receptor not previously reported in platelets, to phosphorylate spleen tyrosine kinase and thus increased Ca2+ influx, protein kinase C activation, and reactive oxygen species production to regulate platelet hyperreactivity. TD139, a Galectin-3 inhibitor in a Phase II clinical trial, concentration dependently suppressed Galectin-3-potentiated platelet activation and inhibited occlusive thrombosis without exacerbating haemorrhage in ApoE-/- mice, which spontaneously developed increased plasma Galectin-3 levels. TD139 also suppressed microvascular thrombosis to protect the heart from myocardial ischaemia-reperfusion injury in ApoE-/- mice. CONCLUSION: Galectin-3 is a novel positive regulator of platelet hyperreactivity and thrombus formation in CAD. As TD139 has potent antithrombotic effects without bleeding risk, Galectin-3 inhibitors may have therapeutic advantages as potential antiplatelet drugs for patients with high plasma Galectin-3 levels.
引用
- Chen Y, Fu W, Zheng Y, et al. Galectin 3 enhances platelet aggregation and thrombosis via Dectin-1 activation: a translational study. Eur Heart J. 2022. PMID: 35165707. doi:10.1093/eurheartj/ehac034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。